해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.13. (금)

 

구분	보고서(영문)
제약/바이오/ 임상시험 (3건)	Bio/Pharmaceutical Outsourcing Report, August 2024
	Migraine Market Expected to Reach $16.4 Billion Across 7MM by 2033
	Emerging Microbiome Market—Unlocking New Frontiers
컨퍼런스/ 심포지엄/ 학회/기타 (17건)	ESC 2024: Obicetrapib - A Promising Breakthrough for Dyslipidemia Treatment
	ESC 2024: SELECT Trial Provides Promising Results for the Treatment of Obesity-Related HFpEF with Semaglutide 2.4mg
	ESC 2024: Additional Analysis of FLOW Trial Highlights That CKD Patients Could Positively Benefit From Ozempic
	ESC 2024: Retatrutide Improves Lipid and Cardiovascular Risk Profile in Phase II Trial
	ESC 2024: Study Highlights Novartis’ Potential to Differentiate in HF Space
	ESC 2024: Sacubitril/Valsartan Continues to Impress in HF
	ESC 2024: FINEARTS-HF Trial Sheds Positive Light on Kerendia for HFmrEF/HFpEF
	ESC 2024: Results From CATHEDRAL-HF Trial Has the Potential to Reduce Polypharmacy
	ESC 2024: GLP-1RAs Lower Cardiovascular Risk in Meta-Analysis of 32,884 Patients
	EASD 2024: Survodutide Shows Promise in Overweight, Obesity, and MASH
	EASD 2024: Novel Insights into Maternal Protection in Type 1 Diabetes
	EASD 2024: Bayer’s Kerendia Continues to Impress with Pooled Analysis
	EASD 2024: Cardiovascular and Inflammatory Markers Decrease after Treatment with Oral GLP-1R Agonist Orforglipron
	EASD 2024: Mazdutide Improves Cardiometabolic Function in Patients with Obesity or Overweight
	EASD 2024: New Developments in Presymptomatic Type 1 Diabetes Screening
	EASD 2024: Are Tetra-Agonists the Future of Metabolic Diseases Treatment?
	EASD 2024: A COMBINEd Approach for Better Diabetes Management
질환별 (5건)	NICE Approves New Osteoporosis Treatment for High-Risk Patients in the UK
	Sickle Cell in September: Spreading Awareness and Supporting Solutions
	Rising ADHD Diagnoses in 7MM Linked to Standardized Screening Tools and Guidelines
	Uterine Leiomyoma: Competitive Landscape
	Dysmenorrhea: Competitive Landscape